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There is an evolving need of high concentration liquid formulations in the field of biologicals over the last years. 
An increase in protein concentration allows administering the desired therapeutic dose preferably within a single 
injection due to a considerably reduced drug product volume. Thus, the usage of high concentrated liquid 
formulations is associated with a higher degree of freedom with regard to e.g. primary packaging material such 
as syringes, small volume applicators as well as route of administration. Both are leading to a higher patient 
convenience, ideally to self-administration and thus hospital or medical personnel independency. However, a 
higher protein concentration can result in increasing viscosities, which entails challenges regarding 
administration to the patient or biopharmaceutical processing steps (e.g. purification, fill and finish). In literature, 
key interactions of high concentration liquid formulations are described, which are of importance for the 
purification (e.g. Donnan effect for diafiltration) or the fill and finish step (e.g. differences in densities). This oral 
presentation will give an overview of obstacles and pitfalls within certain biopharmaceutical processing steps of 
HCLFs as well as approaches to tackle them.  
 
